ReviewFertility and sterility2013
Biomarkers in reproductive medicine: the promise, and can it be fulfilled?
Review in Fertility and sterility, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Technical Verification and Assessment of Independent Validation of Biomarker Models for Endometriosis.BioMed research international · 2019Trial
- Using the Eeva Test™ adjunctively to traditional day 3 morphology is informative for consistent embryo assessment within a panel of embryologists with diverse experience.Journal of assisted reproduction and genetics · 2015Trial
- Evaluation of novel biomarkers for early pregnancy outcome prediction†.Biology of reproduction · 2024Article
- Application of a Multiplex Platform to Identify Novel Biomarkers for Pregnancy Location and Viability.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Application of a Multiplex Platform to Identify Novel Biomarkers for Pregnancy Location and Viability.Research square · 2023Article
- Validation of a multiple marker test for early pregnancy outcome prediction.Journal of assisted reproduction and genetics · 2023Article
- Demetra Application: An integrated genotype analysis web server for clinical genomics in endometriosis.International journal of molecular medicine · 2021Article
- Nanotechnology in reproductive medicine: Opportunities for clinical translation.Clinical and experimental reproductive medicine · 2020Article
- Evaluation, validation and refinement of noninvasive diagnostic biomarkers for endometriosis (ENDOmarker): A protocol to phenotype bio-specimens for discovery and validation.Contemporary clinical trials · 2018Article
- Developing a deeper insight into reproductive biomarkers.Clinical and experimental reproductive medicine · 2017Review
- Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation.Science translational medicine · 2014Article
- Biomarkers identified with time-lapse imaging: discovery, validation, and practical application.Fertility and sterility · 2013Review
- Bringing epigenetics into the diagnostics of the andrology laboratory: challenges and perspectives.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A biomarker can be used for early diagnosis of a disease, identification of individuals for disease prevention, as a potential drug target, or as a potential marker for a drug response. A biomarker may also limit the use of drug (and therefore costs) to the population of patients for which the drug will be safe and efficacious. A biomarker in reproduction could be used to improve assessment of exposure, identify subgroups susceptible to treatment, predict outcome, and/or differentiate subgroups with potentially different etiologies of disease. Despite many potential uses there is low participation in reproductive biology to develop molecular biomarkers, which may be directly related to the low number of new molecular entities entering clinical trials. As the number of candidate markers in reproductive medicine is increasing, it is important to understand the pathway of development from discovery to clinical utility and recognize that the vast majority of potential markers will not be clinically useful, owing to a variety of pitfalls. Extensive testing, validation, and modification needs to be performed before a biomarker is demonstrated to have clinical utility. New opportunities and partnerships exist and should hasten the development of biomarkers in reproduction. As more biomarkers are moved into practice, a better-educated biomarker consumer will enhance the possibility that biomarker(s) will realize their great potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.